文献速递肾癌与肾肿瘤

肿瘤大小在预测部分肾切除术后手术成功方面优于肾肿瘤评分系统

Tumour size outperforms nephrometry scores to predict surgical success following partial nephrectomy.
PubMed 文献 · BJU Int · 2026-02-23

这项回顾性研究基于1787例接受机器人辅助部分肾切除术的患者,评估肿瘤大小与R.E.N.A.L.、PADUA、SPARE三种肾肿瘤评分系统对trifecta、pentafecta及术后急性肾损伤(AKI)的预测能力。结果显示三种评分系统均为显著预测因子但预测性能有限(AUC 0.573-0.645),而肿瘤直径的预测性能更优(AUC 0.649-0.665),且无评分系统能预测12个月肾病进展。

要点

  • 肿瘤直径预测trifecta、pentafecta和AKI优于R.E.N.A.L.、PADUA和SPARE评分。
  • 三种肾肿瘤评分系统预测性能有限,AUC仅0.573-0.645。
  • 无评分系统可预测术后12个月肾病进展。

核心结论

  • 较低的R.E.N.A.L.、PADUA和SPARE评分与手术成功及降低AKI风险相关,但预测性能一般,可被更简单的肿瘤直径超越。

研究设计与样本

  • 回顾性审查IRB批准的前瞻性维护数据库,纳入2011至2024年间接受机器人辅助部分肾切除术的1787例原发性非转移性肾肿块患者。
  • 所有术前影像由单一住院医师审阅并基于肾肿瘤评分系统进行肿瘤特征描述。

主要发现

  • trifecta和pentafecta达成率分别为52.7%和22.2%。
  • 三种肾肿瘤评分系统均为trifecta、pentafecta和术后AKI的显著预测因子,AUC为0.573-0.645。
  • 肿瘤直径预测trifecta和pentafecta的AUC为0.649-0.665,优于肾肿瘤评分系统。
  • 无肾肿瘤评分系统被确定为12个月肾病进展的预测因子。

关键数值与推荐

  • trifecta定义:热缺血时间<25分钟、切缘阴性且无并发症。
  • pentafecta定义:trifecta加上12个月肾功能保留>90%且无肾病进展。

临床怎么用

  • 临床可利用肿瘤直径这一简单客观指标预测RAPN术后手术成功和AKI风险。
  • 肾肿瘤评分系统虽与结局相关,但预测能力有限,不应过度依赖其预测手术成功。

局限性

  • 单中心回顾性设计可能限制普遍性。
  • 影像由单一住院医师审阅,可能存在偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the utility of tumour size, R.E.N.A.L. (Radius, Exophytic/Endophytic, Nearness to collecting system or sinus, Anterior/Posterior, Location), PADUA (Preoperative Aspects and Dimensions Used for an Anatomical), and SPARE (Simplified PADUA R.E.N.A.L.) nephrometry scoring systems (NSs) in predicting the likelihood of achieving trifecta and pentafecta outcomes, as well as the risk of postoperative acute kidney injury (AKI) and kidney disease progression at 12 months following robot-assisted partial nephrectomy (RAPN). PATIENTS AND METHODS: Retrospective review was performed on Institutional Review Board-approved, prospectively maintained database to identify all cases of primary, non-metastatic renal masses who underwent RAPN between 2011 and 2024. All preoperative radiological images were reviewed by a single resident physician, who characterised all tumours based on the NSs. Trifecta outcome was defined as cases with warm ischaemia time of <25 min, negative surgical margin, and absence of complications. Pentafecta included the trifecta outcomes with the addition of >90% renal function preservation and absence of kidney disease progression at 12 months. Logistic regression and receiver operating characteristic (ROC) analyses were completed to determine the predictive ability for the tumour size and each of the NSs. RESULTS: Based on 1787 patients, trifecta and pentafecta were achieved in 52.7% and 22.2%, respectively. All three NSs were established as significant predictors of trifecta, pentafecta, and postoperative AKI, with all demonstrating comparable yet limited predictive performance (area under the ROC curve [AUC] 0.573-0.645). Tumour diameter (AUC 0.649-0.665) was shown to outperform the NSs in predicting the likelihood of achieving trifecta and pentafecta, as well as the risk of AKI. None of the NSs were identified as predictors of kidney disease progression at 12 months. CONCLUSION: Although lower R.E.N.A.L., PADUA, and SPARE NSs were associated with achieving surgical success and reduced risk of AKI, their predictive performance was modest and can be outperformed by a simpler and more objective measure, such as tumour diameter. Future studies remain necessary to re-evaluate the broader clinical utility of NSs in predicting surgical and functional outcomes, in addition to its original purpose as standardized tools for the anatomical characterization of renal tumours.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Soputro NA, Al-Bayati A, Rai S, et al. Tumour size outperforms nephrometry scores to predict surgical success following partial nephrectomy. BJU Int. 2026. PMID: 41730568. doi:10.1111/bju.70181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。